BNP Paribas Financial Markets Grows Position in Exelixis, Inc. (NASDAQ:EXEL)

BNP Paribas Financial Markets increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 88.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 450,097 shares of the biotechnology company's stock after purchasing an additional 211,555 shares during the quarter. BNP Paribas Financial Markets owned 0.14% of Exelixis worth $10,798,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of EXEL. American Century Companies Inc. grew its stake in shares of Exelixis by 31.5% during the 3rd quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company's stock worth $30,811,000 after acquiring an additional 338,021 shares in the last quarter. State of Alaska Department of Revenue grew its stake in shares of Exelixis by 236.3% during the 4th quarter. State of Alaska Department of Revenue now owns 127,287 shares of the biotechnology company's stock worth $3,053,000 after acquiring an additional 89,436 shares in the last quarter. Advisors Preferred LLC bought a new position in shares of Exelixis during the 4th quarter worth approximately $3,384,000. Exchange Traded Concepts LLC grew its stake in shares of Exelixis by 244.5% during the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company's stock worth $2,839,000 after acquiring an additional 83,999 shares in the last quarter. Finally, Seven Eight Capital LP grew its stake in shares of Exelixis by 61.7% during the 3rd quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company's stock worth $476,000 after acquiring an additional 8,305 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Insider Transactions at Exelixis

In related news, Director Jack L. Wyszomierski sold 10,923 shares of the firm's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $21.37, for a total value of $233,424.51. Following the transaction, the director now owns 338,948 shares in the company, valued at $7,243,318.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director David Edward Johnson purchased 190,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 21st. The shares were bought at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the transaction, the director now owns 1,100,730 shares of the company's stock, valued at $22,785,111. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack L. Wyszomierski sold 10,923 shares of the firm's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $21.37, for a total value of $233,424.51. Following the completion of the transaction, the director now owns 338,948 shares in the company, valued at approximately $7,243,318.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,148 shares of company stock valued at $1,703,116. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Stock Down 1.5 %

Shares of EXEL traded down $0.32 during midday trading on Friday, reaching $20.91. 1,548,181 shares of the stock were exchanged, compared to its average volume of 2,284,138. Exelixis, Inc. has a twelve month low of $18.64 and a twelve month high of $24.34. The company has a market cap of $6.34 billion, a P/E ratio of 33.17, a PEG ratio of 0.57 and a beta of 0.57. The stock's 50 day simple moving average is $22.87 and its 200 day simple moving average is $22.28.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The firm had revenue of $425.23 million for the quarter, compared to analyst estimates of $461.04 million. During the same period in the prior year, the business posted $0.12 EPS. The firm's quarterly revenue was up 4.0% compared to the same quarter last year. As a group, analysts predict that Exelixis, Inc. will post 1.16 earnings per share for the current year.

Analysts Set New Price Targets

EXEL has been the subject of several analyst reports. Stifel Nicolaus raised their target price on shares of Exelixis from $23.00 to $25.00 and gave the company a "hold" rating in a research note on Friday, February 2nd. Stephens initiated coverage on shares of Exelixis in a research note on Tuesday. They issued an "equal weight" rating and a $23.00 target price for the company. TheStreet raised shares of Exelixis from a "c+" rating to a "b-" rating in a research note on Monday, March 18th. Royal Bank of Canada raised their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Finally, Barclays cut shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $25.00 target price for the company. in a research note on Thursday, April 11th. Seven investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.13.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.